ADM
Catalysts
Key Risks
The Opportunity
ADM is one of the world's biggest agricultural processors - think of it as a massive middleman between farmers and food companies. The company buys crops like soybeans, corn, and wheat, processes them into oils, sweeteners, animal feed, and food ingredients, then ships them globally through its own network of barges, elevators, and terminals. It's a business that runs on razor-thin margins but enormous volume.
The company just went through a rough patch. In early 2024, it came out that executives had been shuffling money between business units to make one division look more profitable than it really was. The SEC fined ADM $40 million, and there's still a class-action lawsuit working its way through the courts from investors who feel they were misled. That scandal, combined with a natural downturn in commodity processing margins, sent earnings tumbling from $7.71 per share in 2022 down to just $2.23 in 2025.
Here's where it gets interesting: earnings are bouncing back hard. The most recent quarter showed nearly a doubling of profits year-over-year, and management raised its full-year forecast significantly. A big reason is new government rules requiring much more biofuel blending - and ADM's soybean crushing plants are exactly what's needed to produce that fuel. The company is also cutting $500 million in costs and selling off underperforming businesses to get leaner.
The catch is that the stock has already rallied 53% over the past year in anticipation of this recovery. At around $80, the shares are trading roughly in line with - or slightly above - what the business appears to be worth on a normalized basis. The analyst consensus target is actually $77, below today's price. The accounting scandal left a credibility stain on management, the ongoing lawsuit could cost hundreds of millions, and commodity margins are inherently unpredictable. This isn't a broken company, but it's also not a screaming bargain anymore.
For a patient investor, ADM offers a 2.6% dividend yield backed by 53 consecutive years of increases, exposure to structural biofuel demand growth, and a balance sheet that can weather commodity cycles. But at current prices, you're paying roughly fair value for those qualities - the easy money in the recovery trade has already been made.
Breakdown
ADM's Q2 2026 balance sheet shows $53.53B in total assets against $29.66B in liabilities, yielding book equity of $23.58B or $48.93 per share. However, this book value requires significant fair-value adjustments. ADM carries substantial inventory - as a commodity processor, its grain, oilseed, and refined product inventories are marked close to market value and are generally realizable near book.
The company's extensive logistics network of elevators, terminals, barges, and processing plants represents hard-to-replicate physical infrastructure whose replacement cost likely exceeds book value, given decades of construction and permitting. However, goodwill and intangibles from the Nutrition segment acquisitions (Wild Flavors 2014, various specialty ingredient firms) are the most scrutiny-worthy asset. The accounting fraud centered on inflating Nutrition's reported profitability [SEC Charges Against ADM, Jan 2026], which raises the question of whether goodwill impairment tests were conducted on artificially elevated cash flow projections.
The Nutrition segment has underperformed its original 15-20% annual operating profit growth targets [Volkov Law Blog, Mar 2026], suggesting some impairment risk on those acquired intangibles. Net debt stands at approximately $6.95B ($1.56B current + $6.45B LT debt minus $1.06B cash), a manageable level at roughly 2.7x trailing EBITDA. The current ratio of 1.39 is adequate for a commodity processor, though the quick ratio of 0.86 indicates meaningful inventory reliance.
Debt-to-equity of 0.34 is conservative. Overall, the balance sheet is solid but the Nutrition segment goodwill and the post-scandal credibility of prior carrying values introduce moderate uncertainty.
ADM generated $1.68B in free cash flow on a trailing basis, yielding an FCF yield of roughly 4.3% at the current $38.8B market cap. Capital allocation has historically been divided among dividends, share buybacks, and growth investments. The dividend is a centerpiece - ADM is a Dividend Aristocrat with 53 consecutive years of increases [The Top 2 Consumer Staples Stocks, Mar 2026].
However, the current payout ratio of 91.59% is alarmingly high, consuming nearly all reported GAAP earnings. This is partly a function of the 2025 earnings trough ($2.23 EPS against a $2.08 annual dividend). As earnings recover toward the $5.15-$5.60 guided range for 2026, the payout ratio should normalize to 37-40%, which is much healthier.
The company has been an active repurchaser of shares, with the outstanding count declining from roughly 556M in 2019 to 482M today - a meaningful 13% reduction over seven years. The $500M+ cost savings program announced in February 2025 [ADM Q2 2025 8-K], including up to 700 job cuts [Food Dive], represents a significant self-help initiative. Portfolio simplification via the Golden Peanut sale process [Sahm Capital, Oct 2025] and the Alltech animal feed JV [ADM-Alltech JV, Sep 2025] should free up capital for higher-return uses.
The concern is whether management will redeploy capital wisely given the Nutrition segment's track record of value-destructive acquisitions that were then dressed up with accounting adjustments.
ADM's financial track record over the last decade reveals a commodity-cycle-driven business with a clear peak-to-trough pattern. Revenue peaked at $101.6B in 2022 and declined to $80.3B in 2025, a 21% drop driven by lower commodity prices rather than volume loss. EPS followed a similar arc: $7.71 in 2022 down to $2.23 in 2025.
Gross margins have been remarkably tight and consistent for a company of this scale, ranging from 6.2% to 8.0% over the past decade - this is the hallmark of a low-margin, high-volume commodity processor. Operating margins ranged from 1.2% (2025 trough) to 4.4% (2022 peak). The critical story is the Nutrition segment, which was supposed to diversify ADM away from commodity cyclicality.
Instead, it became the center of an accounting fraud - intersegment transfers were used to inflate Nutrition's apparent profitability from 2020-2023 [Volkov Law Blog, Mar 2026]. This means the historical track record during the boom years was partially fabricated for at least one segment. On the positive side, ADM has beaten earnings estimates in every quarter from Q2 2025 through Q2 2026, and the Q2 2026 results ($1.87 reported, adjusted $1.84, vs $1.49 estimate) represent a genuine inflection.
Revenue growth turned positive at 7.2% YoY. The company has delivered consistent dividend growth for 53 years and steady share count reduction. ROE of 7.5% and ROA of 3.3% are modest but reflect the capital-intensive, low-margin nature of the business.
ADM raised its 2026 adjusted EPS guidance to $5.15-$5.60 after the strong Q2 beat [ChartMill, Jul 2026]. At the midpoint of $5.375, this represents a dramatic recovery from the $2.23 trough in 2025 and would put the forward P/E at roughly 15x. Analyst consensus projects 15.4% annualized EPS growth over the next five years, which implies EPS reaching roughly $10-$11 by 2031.
This seems aggressive for a commodity processor. A more conservative estimate would use a normalized EPS of $4.50-$5.50 (the midrange of the cycle) growing at 5-7% through a combination of share buybacks (1-2% annualized), cost savings ($500M program contributing approximately $1.00/share by 2029), and modest organic volume growth. The EPA's finalized biofuel mandates requiring 5.61B gallons of biomass-based diesel in 2026 and 5.86B gallons in 2027 [EPA RFS Rule; Holland & Knight, Apr 2026] provide a structural tailwind for soybean oil crush demand.
However, crush margins are inherently volatile and the Q2 2026 strength may not persist. The reverse DCF implies the market is pricing in 8.5% growth - reasonable but above what I'd consider sustainable long-term for this business. The PEG ratio of 0.97 suggests the stock is roughly fairly valued on a growth-adjusted basis.
Key assumption: I use a normalized EPS of $5.00, growing at 6-8% annually, which captures the cost savings benefit and biofuel tailwind while discounting the cyclical peak in crush margins.
ADM's moat derives from its physical infrastructure and scale advantages. The company operates one of the world's largest networks of grain elevators, processing plants, transportation assets (barges, rail cars, trucks), and port facilities. This logistical infrastructure took decades and billions to build and would be extremely difficult for a new entrant to replicate.
ADM processes approximately 100 million metric tons of volume annually, though this ranks third behind Cargill (~217M MT) and Bunge (~142M MT) [ForesightIQ]. The ABCD oligopoly (ADM, Bunge, Cargill, Louis Dreyfus) still controls roughly 50-60% of global agricultural trade, though this share has compressed from 70-90% as Chinese state-backed Cofco International has gained ground [UkrAgroConsult]. The moat is narrow rather than wide: while the physical infrastructure creates barriers, the underlying business is commodity processing with thin margins (gross margin under 7%).
Customers can and do switch between processors based on price and logistics. The Nutrition segment was intended to build a wider moat through specialty ingredients and higher switching costs, but that strategy's credibility has been damaged by the accounting scandal. The biofuel processing capability adds some differentiation as EPA mandates create regulated demand floors.
Overall, the moat is real but narrow - it protects market share more than it protects margins.
Management assessment must be significantly discounted by the accounting fraud. CEO Juan Luciano has led ADM since 2014 and was named board chairman effective January 2026 [Food Dive]. His tenure oversaw both the revenue growth era and the Nutrition segment accounting manipulation.
The SEC charged former Nutrition President Vince Macciocchi and former Vice Chairman/CFO Ray Young with fraud [SEC.gov, Jan 2026]. While Luciano was not individually charged, the class action lawsuit names him among defendants [Hagens Berman, Mar 2024]. The $40M SEC settlement and DOJ dropping criminal charges represent resolution of the corporate liability, but the securities class action survived a motion to dismiss in March 2025 [DTN/Progressive Farmer, Mar 2025], indicating a court found sufficient evidence to proceed.
On the positive side, ADM hired a new Chief Accounting Officer from Cargill in early 2025 [TipRanks, 2025] - a credibility signal. The appointment of Jeffrey Rowe (former Syngenta CEO) as COO effective August 2026 [GuruFocus, 2026] is a significant operational hire. Insider ownership at 0.68% is very low for a company of this size, which limits management alignment with shareholders.
Insider transactions show only director equity awards with no open-market purchases, and institutional ownership has declined by 7.4% quarter-over-quarter [TradingKey]. Luciano's total compensation of ~$23.9M is substantial. The capital allocation track record is mixed: the share repurchase program has been well-executed, but Nutrition acquisitions destroyed value.
The most material near-term risk is the ongoing securities fraud class action, which survived a motion to dismiss in March 2025 [DTN/Progressive Farmer, Mar 2025] and covers purchasers from April 2020 to January 2024. Settlement or adverse judgment could represent hundreds of millions in additional liability beyond the $40M already paid to the SEC. Commodity price volatility is an inherent and permanent risk - crush margins can swing dramatically quarter to quarter, as evidenced by the swing from $0.22 EPS in Q3 2025 to $1.87 in Q2 2026.
The biofuel regulatory environment is a double-edged sword: while current EPA mandates are favorable [EPA RFS Rule], future administrations could alter renewable fuel standards. Competitive intensity is increasing as Cofco International gains global market share [UkrAgroConsult], and Bunge's Viterra acquisition strengthens a key public competitor [WallStreetZen / Koala Gains]. The high payout ratio of 91.59% creates risk if earnings don't recover as guided - though the 2026 guidance raise substantially mitigates this.
The Nutrition segment restructuring carries execution risk: the shift toward specialty ingredients and the Alltech JV [ADM-Alltech JV, Sep 2025] need to deliver margin improvement to justify the strategic pivot. Currency and trade policy risks are meaningful given ADM's global operations across dozens of countries.
The global fats and oils market is growing at approximately 5-6% CAGR, with specialty fats and oils growing faster at 7.5% [Fortune Business Insights]. The EPA's finalized biofuel mandates for 2026-2027 represent a major structural tailwind, increasing biomass-based diesel blending requirements by 67-75% versus 2025 levels [Holland & Knight, Apr 2026; US EPA]. International biofuel mandates in Indonesia (B50) and Brazil (B16) further support soybean oil demand [S&P Global, Dec 2025].
The protein ingredients market ($83B growing to $122B by 2031) and feed additives market ($51B to $68B by 2031) represent additional growth vectors for ADM's portfolio [Protein Ingredients Market; Feed Additives Market]. Among the ABCD peers, ADM is the smallest public pure-play by processing volume. Bunge is considered to have a more compelling near-term investment case by some analysts [WallStreetZen].
Institutional ownership remains high at 87.6% but has been declining, with Vanguard holding ~5.4% [SEC 13G, 2026]. No activist campaigns or takeover interest have been identified. The analyst consensus recommendation of 3.27 (between hold and underperform) reflects lingering caution, and the consensus target of $77.11 sits below the current $80.45 price, suggesting the stock may have run ahead of fundamentals on the Q2 beat momentum.